Boceprevir Officially Fast-Tracked
Merck’s new oral hepatitis C drug boceprevir will receive fast track reviews from both the FDA and the EMA after the regulators decided it marked a major advance in treatment.
The FDA has granted Merck’s investigational protease inhibitor priority review status, a move that could see the drug on the market within six months.
The US regulator’s European counterpart the EMA has also accepted the marketing Merck’s boceprevir application for accelerated assessment.
Continue reading this entire article:
IP-10 Protein Levels Predict Hepatitis C Treatment Outcome
Early Hepatitis C Trial Data Shows INX-189 to Be Effective